60 Degrees Pharmaceuticals Llc

This phase 2 study tests the drug tafenoquine in 40 adults with chronic babesiosis who have severe fatigue. The goal is to see if tafenoquine can reduce fatigue and clear the Babesia parasite from the blood. Participants take the drug and report their fatigue levels using a stand…

This expanded access program provides tafenoquine, an antimalarial drug, to immunocompromised patients with persistent babesiosis (a tick-borne illness) who haven't gotten better with standard treatments. Participants take the drug daily for 4 days, then weekly until they test ne…

This study tests whether adding the antimalarial drug tafenoquine to standard care helps hospitalized babesiosis patients recover faster. About 33 adults with confirmed Babesia infection will receive either tafenoquine or a placebo, plus standard antibiotics. Researchers will tra…